August 4, 2022

Dear COVID-19 Therapeutic Provider,

Bebtelovimab will become available for purchase from the distributor AmerisourceBergen (ABC) during the week of August 15, 2022. Distribution of bebtelovimab that was purchased by the United States government (USG) and distributed to providers through state allocation will end in mid-August.

- The purchase cost per patient course of bebtelovimab will be $2,100
- CMS reimbursement cost for the medication for Medicaid and Medicare patients is pending and will be posted here when it is available.
- An AmerisourceBergen account is required to purchase bebtelovimab. Contact asdaccountsetup@amerisourcebergen.com to set up an ABC account.
- For questions about purchasing bebtelovimab, contact c19therapies@amerisourcebergen.com.
- ABC will not take returns of purchased bebtelovimab for refunds.

Providers may submit requests for bebtelovimab in HPOP for allocation of remaining federally-purchased product before 5pm CT on Friday August 12, 2022.

Facilities must continue to report transfers, wastage, and administration and on-hand inventory in HPOP of all USG-purchased bebtelovimab until this supply is depleted. Providers MAY NOT seek reimbursement for the bebtelovimab that was distributed at no cost from USG and should keep this stock separated from any product that is purchased.

The USG has requested that providers reserve the USG-purchased bebtelovimab for uninsured and underinsured patients that are not able to take or access Paxlovid or Veklury (remdesivir), the top-recommended therapeutics. In addition to bebtelovimab, Lagevrio (molnupiravir) is the other alternative therapy recommended by the National Institutes of Health (NIH) for the outpatient treatment of COVID-19 illness in high-risk individuals. See side-by-side overview of COVID-19 outpatient therapeutics.

Thank you for the work you are doing to take care of Texans with COVID-19.